Stress Reduction in Ovarian Cancer
Conditions
Ovarian, Fallopian, and Primary Peritoneal Cancer
Study Type
Interventional
Study Phase
N/A
Study Design
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care
Intervention
Name: Daily stress reduction program Type: Behavioral
Name: Attention control Type: Other
Overall Status
Recruiting
Summary
The purpose of this study is to investigate the effects of a stress reduction program on the quality of life of ovarian cancer patients during primary adjuvant chemotherapy.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Female
Criteria: Inclusion Criteria:

- Subjects must have an initial diagnosis of ovarian, fallopian tube or primary peritoneal cancer who completed primary ovarian cancer surgery or 3 cycles of neoadjuvant chemotherapy with interval cytoreductive surgery (ICS).

- Final pathology diagnosis of stage I-IV ovarian, fallopian tube or primary peritoneal cancer with plan to receive primary adjuvant chemotherapy or completion of chemotherapy after ICS.

- Receive chemotherapy at the University of Wisconsin-Madison.

- Subjects must be at least 18 years of age.

- English-speaking

- Subjects must be able to use audio media, and read and understand the study manual.

- ECOG performance status 0-2.

- Subjects must have a phone.

Exclusion Criteria:

- Subjects participating in a meditation practice more than 1 hour per week prior to surgery and/or chemotherapy administration.

- Subjects with recurrent ovarian, fallopian tube or primary peritoneal cancer.

- Subjects with diagnosis of Chronic Fatigue Syndrome (CFS).

- Subjects unable to use audio media due to auditory dysfunction.

- Subjects unable to read written English.

- Subjects who are prisoners or incarcerated.
Location
University of Wisconsin School of Medicine and Public Health
Madison, Wisconsin, United States
Status: Recruiting
Contact: Cancer Connect - 800-622-8922
Start Date
February 2013
Completion Date
December 2016
Sponsors
University of Wisconsin, Madison
Source
University of Wisconsin, Madison
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page